Skip to content

Newsroom

type
year
reltype
Illustration image.png

Orion and Save the Children Finland announce cooperation to promote well-being of children in Finland and globally

2/22/2024 Press release
Illustration image.png

Orion to investigate the possible outsourcing of its pharmaceutical production in Kuopio, Finland

2/19/2024 Press release
Illustration image.png

Notice to the Annual General Meeting of Orion Corporation

2/13/2024 Stock exchange release
Illustration image.png

Orion Group Financial Statement Release January–December 2023

2/13/2024 Stock exchange release
Illustration image.png

119,021 Orion Corporation A shares converted into B shares

2/7/2024 Stock exchange release
Illustration image.png

Orion publishes Financial Statement Release for 2023 and holds a webcast on 13 February 2024

1/29/2024 Press release
Illustration image.png

Orion Corporation and Newel Health enter into licensing agreement for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in pain

1/29/2024 Press release
Illustration image.png

Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024

1/26/2024 Press release
Illustration image.png

Change in Orion Group Executive Management Board – René Lindell appointed Chief Financial Officer of Orion

1/23/2024 Stock exchange release
Illustration image.png

Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2024 Annual General Meeting

1/11/2024 Stock exchange release
Illustration image.png

Insurance portfolio of Orion Pension Fund’s B fund transferred to an external pension insurance company – the transfer has approximately EUR 31 million positive impact on Orion’s result in 2023

1/11/2024 Stock exchange release
Illustration image.png

Orion Corporation: Managers’ transactions – Ari Lehtoranta

1/8/2024 Managers transactions
Illustration image.png

Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs

1/8/2024 Press release
Illustration image.png

Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer

1/5/2024 Press release
Illustration image.png

NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208

12/27/2023 Press release
Illustration image.png

87 000 Orion Corporation A shares converted into B shares

12/4/2023 Stock exchange release
Illustration image.png

Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov database

11/21/2023 Press release
Illustration image.png

Orion Animal Health receives FDA approval for Bonqat® (pregabalin oral solution)

11/20/2023 Press release